PMID- 32274930
OWN - NLM
STAT- MEDLINE
DCOM- 20201231
LR  - 20221207
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 54
IP  - 10
DP  - 2020 Oct
TI  - Weight Outcomes With Empagliflozin as Compared With Liraglutide in Veterans With 
      Type 2 Diabetes Mellitus.
PG  - 981-987
LID - 10.1177/1060028020915791 [doi]
AB  - BACKGROUND: Glucagon-like peptide-1 agonists and sodium glucose cotransporter 2 
      inhibitors are associated with weight loss and improved cardiovascular outcomes, 
      and are increasingly used in pharmacotherapy for type 2 diabetes mellitus (T2DM). 
      OBJECTIVES: To compare weight loss outcomes of empagliflozin and liraglutide in 
      patients with T2DM and overweight/obesity not yet prescribed insulin but 
      requiring additional pharmacotherapy to improve glycemic control. METHODS: This 
      is an observational, multisite, cohort study of veterans with T2DM prescribed 
      liraglutide or empagliflozin. Participants were prescribed either empagliflozin 
      or liraglutide prior to November 1, 2017, had a hemoglobin A(1C) (A1C) >/=7.0%, had 
      a body mass index >/=27 kg/m(2), and were not treated with insulin at baseline. The 
      primary outcome was change in weight after 1 year using multiple regression. 
      Secondary outcomes were the proportion achieving >/=5% weight loss and change in 
      A1C. RESULTS: Weight loss was not significantly different between groups: -2.17 
      kg (95% CI: -2.91 to -1.42) in the liraglutide group (n = 298) and -2.81 kg (95% 
      CI: -3.43 to -2.20) in the empagliflozin group (n = 247; P > 0.05). After 
      adjusting for covariates, this effect remained nonsignificant. There was no 
      difference in change in A1C between liraglutide (-0.83%; 95% CI: -1.05% to 
      -0.62%) and empagliflozin (-0.71%; 95% CI: -0.89% to -0.53%; P > 0.05). 
      CONCLUSIONS AND RELEVANCE: There was no significant difference in weight outcomes 
      after 1 year in veterans treated with liraglutide versus empagliflozin. Because 
      both medications did show modest weight loss, both remain good options for 
      patients needing an additional medication to improve glycemic control that is at 
      least weight neutral.
FAU - Grabarczyk, Ted Robert
AU  - Grabarczyk TR
AUID- ORCID: 0000-0002-5048-2154
AD  - Department of Veterans Affairs Eastern Kansas Health Care System, Topeka, KS, 
      USA.
FAU - Wissman, Natalie Koury
AU  - Wissman NK
AD  - Department of Veterans Affairs Eastern Kansas Health Care System, Topeka, KS, 
      USA.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200410
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (GLP1R protein, human)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 839I73S42A (Liraglutide)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Benzhydryl Compounds/*therapeutic use
MH  - Body Weight/drug effects
MH  - Cohort Studies
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy
MH  - Female
MH  - Glucagon-Like Peptide-1 Receptor/*agonists
MH  - Glucosides/*therapeutic use
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Liraglutide/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Obesity/complications/*drug therapy
MH  - Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use
MH  - Veterans
OTO - NOTNLM
OT  - diabetes mellitus
OT  - empagliflozin
OT  - liraglutide
OT  - obesity
OT  - weight loss
EDAT- 2020/04/11 06:00
MHDA- 2021/01/01 06:00
CRDT- 2020/04/11 06:00
PHST- 2020/04/11 06:00 [pubmed]
PHST- 2021/01/01 06:00 [medline]
PHST- 2020/04/11 06:00 [entrez]
AID - 10.1177/1060028020915791 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2020 Oct;54(10):981-987. doi: 10.1177/1060028020915791. Epub 
      2020 Apr 10.